Sun Pharma launches Noveltreat and Sematrinity injections in India

Arunika Jain — Sat, 21 Mar 2026 06:27:25 +0000

Sun Pharmaceutical Industries has announced the launch of its semaglutide injection under the brand names Noveltreat and Sematrinity in India. The launch includes all strengths of the medication, aimed at providing affordable treatment options for chronic weight management and type 2 diabetes mellitus.

Noveltreat is designed for chronic weight management in adults and is available in five dose strengths: 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, and 2.4 mg/0.75 mL. It is intended to be used as an adjunct to a reduced calorie diet and increased physical activity. Sematrinity, on the other hand, is indicated for adults with insufficiently controlled type 2 diabetes mellitus and comes in two dose strengths: 2 mg/1.5 mL and 4 mg/3 mL.

The pricing strategy for these products aims to enhance affordability, with weekly therapy costs ranging from approximately ₹900 to ₹2,000 for Noveltreat and ₹750 to ₹1,300 for Sematrinity. This is significantly lower than the innovator brand.

Kirti Ganorkar, Managing Director of Sun Pharmaceutical Industries, commented on the launch, emphasising the company’s commitment to offering high-quality, affordable therapies. He highlighted the introduction of a holistic patient support programme designed to assist patients throughout their treatment journey.

Noveltreat features a prefilled pen with a concealed needle to reduce injection fear and improve safety and dosing accuracy. Sematrinity is provided in a multi-dose pen format that allows for flexible dosing, with a smooth dialer for accurate dose delivery. These pens, developed by leading global pharmaceutical device suppliers, are manufactured in Europe.

GLP-1 agonists, including semaglutide, are highly effective for treating type 2 diabetes mellitus and obesity, reducing cardiovascular and renal morbidity and mortality. With obesity and diabetes being significant health concerns in India, the introduction of these medications aims to address the urgent need for effective treatment options.

Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).

Sematrinity | Business Upturn

Sun Pharma launches Noveltreat and Sematrinity injections in India